Literature DB >> 27270275

Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients.

Larry K Kociolek1, Dale N Gerding2, James R Osmolski3, Sameer J Patel4, David R Snydman5, Laura A McDermott6, David W Hecht3.   

Abstract

The rising incidence of Clostridium difficile infections (CDIs) in adults is partly related to the global spread of fluoroquinolone-resistant strains, namely, BI/NAP1/027. Although CDIs are also increasingly diagnosed in children, BI/NAP1/027 is relatively uncommon in children. Little is known about the antibiotic susceptibility of pediatric CDI isolates. C. difficile was cultured from tcdB-positive stools collected from children diagnosed with CDI between December 2012 and December 2013 at an academic children's hospital. CDI isolates were grouped by restriction endonuclease analysis (REA). MICs were measured by agar dilution method for 7 antibiotics. Susceptibility breakpoints were based on guidelines from CLSI and/or the European Committee on Antimicrobial Susceptibility Testing (EUCAST). MICs and REA groupings of C. difficile isolates from 74 adult patients (29 isolates underwent REA) from a temporally and geographically similar adult cohort were compared to those of pediatric isolates. Among 122 pediatric and 74 adult isolates, respectively, the rates of resistance were as follows: metronidazole, 0% and 0%; vancomycin, 0% and 8% (P = 0.003); rifaximin, 1.6% and 6.7% (P = 0.11); clindamycin, 18.9% and 25.3% (P = 0.29); and moxifloxacin, 2.5% and 36% (P = <0.0001). Only 1 of 122 (0.8%) BI/NAP1/027 isolates was identified among the children, compared to 9 of 29 (31%) isolates identified among the adults (P = <0.0001). The 3 moxifloxacin-resistant pediatric isolates were of REA groups BI and CF and a nonspecific group. The 2 rifaximin-resistant pediatric isolates were of REA groups DH and Y. The 21 clindamycin-resistant pediatric isolates were distributed among 9 REA groups (groups A, CF, DH, G, L, M, and Y and 2 unique nonspecific REA groups). These data suggest that a diverse array of relatively antibiotic-susceptible C. difficile strains predominate in a cohort of children with CDI compared to adults.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27270275      PMCID: PMC4958144          DOI: 10.1128/AAC.00714-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

Review 1.  Clostridium difficile--more difficult than ever.

Authors:  Ciarán P Kelly; J Thomas LaMont
Journal:  N Engl J Med       Date:  2008-10-30       Impact factor: 91.245

2.  Risk Factors for Recurrent Clostridium difficile Infection in Children: A Nested Case-Control Study.

Authors:  Larry K Kociolek; Hannah L Palac; Sameer J Patel; Stanford T Shulman; Dale N Gerding
Journal:  J Pediatr       Date:  2015-05-19       Impact factor: 4.406

Review 3.  Breakthroughs in the treatment and prevention of Clostridium difficile infection.

Authors:  Larry K Kociolek; Dale N Gerding
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-10       Impact factor: 46.802

4.  Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems.

Authors:  C R Clabots; S Johnson; K M Bettin; P A Mathie; M E Mulligan; D R Schaberg; L R Peterson; D N Gerding
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

5.  U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin.

Authors:  D R Snydman; L A McDermott; N V Jacobus; C Thorpe; S Stone; S G Jenkins; E J C Goldstein; R Patel; B A Forbes; S Mirrett; S Johnson; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

6.  In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.

Authors:  David W Hecht; Minerva A Galang; Susan P Sambol; James R Osmolski; Stuart Johnson; Dale N Gerding
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

7.  Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium difficile.

Authors:  K H Wilson; M J Kennedy; F R Fekety
Journal:  J Clin Microbiol       Date:  1982-03       Impact factor: 5.948

8.  Novel risk factors for recurrent Clostridium difficile infection in children.

Authors:  Maribeth R Nicholson; Isaac P Thomsen; James C Slaughter; C Buddy Creech; Kathryn M Edwards
Journal:  J Pediatr Gastroenterol Nutr       Date:  2015-01       Impact factor: 2.839

9.  Multistate point-prevalence survey of health care-associated infections.

Authors:  Shelley S Magill; Jonathan R Edwards; Wendy Bamberg; Zintars G Beldavs; Ghinwa Dumyati; Marion A Kainer; Ruth Lynfield; Meghan Maloney; Laura McAllister-Hollod; Joelle Nadle; Susan M Ray; Deborah L Thompson; Lucy E Wilson; Scott K Fridkin
Journal:  N Engl J Med       Date:  2014-03-27       Impact factor: 91.245

10.  Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection.

Authors:  Milagros Gonzales; Jacques Pepin; Eric H Frost; Julie C Carrier; Stephanie Sirard; Louis-Charles Fortier; Louis Valiquette
Journal:  BMC Infect Dis       Date:  2010-12-30       Impact factor: 3.090

View more
  3 in total

1.  Comparative genomics analysis of Clostridium difficile epidemic strain DH/NAP11/106.

Authors:  Larry K Kociolek; Dale N Gerding; David W Hecht; Egon A Ozer
Journal:  Microbes Infect       Date:  2018-01-31       Impact factor: 2.700

2.  Barriers and facilitators and the need for a clinical guideline for microbiological diagnostic testing in the hospital: a qualitative and quantitative study.

Authors:  Saskia J Bogers; Frederike V van Daalen; Sacha D Kuil; Menno D de Jong; Suzanne E Geerlings
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-03-07       Impact factor: 3.267

3.  Molecular Epidemiology and Antimicrobial Resistance of Clostridioides difficile in Hospitalized Patients From Mexico.

Authors:  Emmanuel Aguilar-Zamora; Bart C Weimer; Roberto C Torres; Alejandro Gómez-Delgado; Nayeli Ortiz-Olvera; Gerardo Aparicio-Ozores; Varenka J Barbero-Becerra; Javier Torres; Margarita Camorlinga-Ponce
Journal:  Front Microbiol       Date:  2022-03-10       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.